Here, we sought to analyze if the relationship between obesity and adverse clinical and pathological characteristics, primary treatment response, and disease outcome in HER2-positive early BC patients treated in the setting of a large prospective randomized clinical trial such as NeoALTTO [8]. The gene discussed is ERBB2; the disease is obesity disorder.